Robert's Feed
Apr 15, 2015
via Breakingviews

EU’s competition sprawl as worrying as Google’s

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

The European Union’s competition sprawl is as worrying as Google’s. Trustbusters on Wednesday accused the $360 billion web giant of favoring its own shopping search results – and broadened the case to include its Android mobile operating system. Investigations and appeals may take a decade. Brussels is going down the same treacherous path as ever-expanding Google.

Apr 6, 2015
via Breakingviews

Request for IBM activism likely falls on deaf ears

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

Requests from some big unnamed shareholders for activism at IBM are likely to fall on deaf ears. No question investors in the company run by Ginni Rometty have reason to be dissatisfied. Big Blue’s top line has shrunk for 11 straight quarters. The IT giant’s shares have fallen about 25 percent from their high, and there’s no hint that the company has figured out a way to reverse course. The snag is that activists don’t have an obvious playbook for IBM’s recovery either.

Apr 6, 2015
via Breakingviews

Request for IBM activism likely falls on deaf ears

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

Requests from some big unnamed shareholders for activism at IBM are likely to fall on deaf ears. No question investors in the company run by Ginni Rometty have reason to be dissatisfied. Big Blue’s top line has shrunk for 11 straight quarters. The IT giant’s shares have fallen about 25 percent from their high, and there’s no hint that the company has figured out a way to reverse course. The snag is that activists don’t have an obvious playbook for IBM’s recovery either.

Mar 30, 2015
via Breakingviews

$12.8 bln prescription may clear up pharmacy M&A

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own. 

A $12.8 billion prescription may clear up pharmacy benefit managers’ chronic M&A. UnitedHealth Group is paying a 27 percent premium for drug middleman Catamaran and should generate more than enough savings to cover it. That might sound like a concoction others might want to try. But the buyer is playing catch-up. And its target is usually a buyer. Catamaran’s capitulation indicates benefit managers no longer need a dose of dealmaking.

Mar 24, 2015
via Breakingviews

Google’s CFO search should have it feeling lucky

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Google’s CFO search should have it feeling lucky. There’s a dearth of executives with the financial, tech and government know-how needed to help run a $400 billion company. Even fewer women fit the bill. Silicon Valley and Wall Street just can’t find people like Morgan Stanley Chief Financial Officer Ruth Porat fast enough. The challenge is to create more like her.

Mar 24, 2015
via Breakingviews

Google’s CFO search should have it feeling lucky

Photo

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

Google’s CFO search should have it feeling lucky. There’s a dearth of executives with the financial, tech and government know-how needed to help run a $400 billion company. Even fewer women fit the bill. Silicon Valley and Wall Street just can’t find people like Morgan Stanley Chief Financial Officer Ruth Porat fast enough. The challenge is to create more like her.

Mar 16, 2015
via Breakingviews

Valeant’s $11 bln bid may have scored two knockouts

Photo

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

The sweetened $11 billion bid by Valeant Pharmaceuticals for Salix Pharmaceuticals may have scored two knockouts. By stumping up an extra 10 percent from its previous offer, the acquisitive drugmaker now backed by hedge fund boss Bill Ackman put rival suitor Endo International on the mat. The extra cash required, and the debt already on its balance sheet, leave Valeant’s business model looking wobbly.

Mar 16, 2015
via Breakingviews

Valeant’s $11 bln bid may have scored two knockouts

Photo

By Robert Cyran

The author is a Reuters Breakingviews columnist. The opinions expressed are his own.

The sweetened $11 billion bid by Valeant Pharmaceuticals for Salix Pharmaceuticals may have scored two knockouts. By stumping up an extra 10 percent from its previous offer, the acquisitive drugmaker now backed by hedge fund boss Bill Ackman put rival suitor Endo International on the mat. The extra cash required, and the debt already on its balance sheet, leave Valeant’s business model looking wobbly.

Mar 6, 2015
via Breakingviews

Apple entry into DJIA is polish for an antique

Photo

By Robert Cyran and Richard Beales

The authors are Reuters Breakingviews columnists. The opinions expressed are their own.

Apple’s entry into the Dow Jones industrial average is a bit like polishing an antique. The average share price of 30 stocks selected by committee will finally include the world’s biggest company in place of AT&T. It’s an overdue move for an outdated yardstick – one which, like landlines and checkbooks, lives on.

Mar 6, 2015
via Breakingviews

Apple entry into DJIA is polish for an antique

Photo

By Robert Cyran and Richard Beales

The authors are Reuters Breakingviews columnists. The opinions expressed are their own.

Apple’s entry into the Dow Jones industrial average is a bit like polishing an antique. The average share price of 30 stocks selected by committee will finally include the world’s biggest company in place of AT&T. It’s an overdue move for an outdated yardstick – one which, like landlines and checkbooks, lives on.

    • About Robert

      "Robert Cyran, U.S. tech columnist, joined Breakingviews in London in 2003 and moved four years later to New York, where he continues to cover global technology, pharmaceuticals and special situations. Robert began his career at Forbes magazine, where he assisted in the start-up of the international version of the magazine. Before working at Breakingviews he worked as a market researcher and reporter covering the pharmaceutical industry. Robert has a Masters degree in economics from Birmingham University and an undergraduate degree from George Washington University."
    • Follow Robert